Cowen Starts Heron Therapeutics (HRTX) at Outperform

Cowen initiates coverage on Heron Therapeutics (NASDAQ: HRTX) with a Outperform rating and a price target of $40.00.

Analyst Boris Peaker commented, "We are initiating coverage of Heron Therapeutics with an Outperform rating and a $40/share price target. Heron’s lead product, Sustol, features best-in-class efficacy and is ideally positioned in the CINV market. Heron’s platform has also generated several other candidates which improve on leading drugs in CINV and postoperative pain."

For an analyst ratings summary and ratings history on Heron Therapeutics click here. For more ratings news on Heron Therapeutics click here.

Shares of Heron Therapeutics closed at $29.39 yesterday.

You May Also Be Interested In

• H.C. Wainwright Downgrades Heron Therapeutics (HRTX) to Neutral
• Intuit (INTU) PT Raised to $328 at TD Cowen
• Stifel Reiterates Buy Rating on Analog Devices (ADI), Expects Solid Q3 Results